


**A****B**



- Informed Consent
- Inclusion/ Exclusion Criteria
- Demographics
- Medical History
- Physical Exam
- **PASI, PGA, BSA**
- **DBP Application**

- Occurs 1 week ( $\pm 3$  days) from baseline
- **DBP Application**


- Occurs 4 weeks ( $\pm 3$  days) from baseline
- **PASI, PGA, BSA**
- **DBP Application**

- Occurs 8 weeks ( $\pm 3$  days) from baseline
- **DBP Application**



- Occurs 12 weeks ( $\pm 3$  days) from baseline
- **PASI, PGA, BSA**
- **DBP Application**

- Occurs 16 weeks ( $\pm 3$  days) from baseline
- **PASI, PGA, BSA**
- **DBP Application**

**Color Key  
and Histogram**



**n=66**




- ENSG00000241794
- ENSG00000206073
- ENSG00000184330
- ENSG00000196805
- ENSG00000143546
- ENSG00000186832
- ENSG00000057149
- ENSG00000124102
- ENSG00000143556
- ENSG00000075673
- ENSG00000140519
- ENSG00000206072
- ENSG00000185479
- ENSG00000244094
- ENSG00000163216
- ENSG00000181333
- ENSG00000205420
- ENSG00000170465
- ENSG00000163220
- ENSG00000111335
- ENSG00000185966
- ENSG00000281194
- ENSG00000148346
- ENSG00000171711
- ENSG00000229035
- ENSG00000148600
- ENSG00000189182
- ENSG00000281508
- ENSG00000184258
- ENSG00000196557

# IL-17i Responders



Source: Tomalin LE, et al, *J Allergy Clin Immunol*, 2020, 145:922-932.

<b>PPV</b>	<b>BALANCED ACCURACY</b>
<b>&gt;90%</b>	<b>&gt;93%</b>



<b>PPV</b>	<b>&gt;92%</b>
<b>SENSITIVITY</b>	<b>79%</b>
<b>SPECIFICITY</b>	<b>86%</b>



### PATIENT REPORT

#### PATIENT

Patient name: **John Doe**  
Sample ID: **0000000**  
Date of birth: **01/10/1965**

#### ORDER

Date specimen collected: **03/10/2020**  
Date of report: **03/28/2020**  
Ordering physician: **Dr. Janet Doe**  
Clinic/hospital: **Smallville Dermatology**  
**000 Street Name**  
**Smallville, KS**



### TEST RESULTS

**R**  
**Responder**

**TNF $\alpha$  Inhibitor**  
*Tumor Necrosis Factor  
Alpha Inhibitor*

**NR**  
**Non-Responder**

**IL-17 Inhibitor**  
*Interleukin 17 Inhibitor*

**R**  
**Responder**

**IL-23 Inhibitor**  
*Interleukin 23 Inhibitor*


# One Treatment Does Not Fit All




Patients with Skin Disease (e.g., Psoriasis)




Biologic



Effective



Ineffective



Negative Effect

# Personalized Approach Yields Better Outcomes



Patients with Skin Disease (e.g., Psoriasis)




mind.px™



Biologic 1




Effective



Biologic 2



Effective



Biologic 3



Effective